openPR Logo
Press release

Rottapharm's Documentation goes paperless with PAS-X

09-10-2009 07:46 PM CET | IT, New Media & Software

Press release from: Werum Software & Systems

Rottapharm's production site in Dublin (Source: Rottapharm)

Rottapharm's production site in Dublin (Source: Rottapharm)

Werum to deliver a functional complete PAS-X-based MES

Lueneburg, Germany, September 8, 2009 - The Italian pharma group Rottapharm is introducing PAS-X at its Irish production site in Dublin. With the transition towards paperless production and documentation, the multinational company will be making its production processes more efficient and increasing output levels. Werum will be implementing a complete PAS-X-based MES, including integration with the SCADA level.

Rottapharm manufactures ethical pharmaceuticals, over the counter and non-prescription drugs, personal care products and nutritional supplements. The therapeutic focus of the pharmaceutical products is cardiology, gastroenterology, gynecology, urology and rheumatology.

Rottapharm established operations in Ireland in 1999. In Dublin, Rottapharm is investing seven million Euros in three new manufacturing and associated packaging lines, which will create 35 jobs and add 2000 square meters. The site employs 150 people in total and primarily manufactures capsule, sachet and tablet forms of the Glucosamine Sulfate Dona, a drug for treating osteoarthritis. The facility also produces the API for Dona.

Werum Software & Systems (www.werum.com) is the leading supplier of Manufacturing Execution Systems (MES) for the pharmaceutical and bio-pharmaceutical industries worldwide. Fourteen of the world's top 20 pharmaceutical companies and leading biotech companies use Werum's MES product suite PAS-X to run their manufacturing business. Outstanding PAS-X features are the functions ensuring compliance and boosting performance. Werum's solutions and services range from software consulting, creation of functional specifications, and software development to turn-key delivery of integrated and validated MES. A global partner network ensures reliable local support services. Founded in 1969, the IT company employs 315 people at different locations. Werum is headquartered in Lueneburg (Northern Germany) and has regional offices in St. Augustin and Hausach. Its U.S. subsidiary Werum America is headquartered in Parsippany, New Jersey, and has additional offices in Cary, North Carolina, and in Pasadena, California.

Werum Software & Systems, Tel. USA +1 (973) 644-4000, Tel. Europe +49 (0)4131 8900-0, Press Contact: Volker Mensing, mensing@werum.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rottapharm's Documentation goes paperless with PAS-X here

News-ID: 95879 • Views:

More Releases from Werum Software & Systems

13th PAS-X User Group Meeting in Germany
13th PAS-X User Group Meeting in Germany
13th PAS-X User Group Meeting in Germany Werum Manufacturing IT Conference with record attendance Lueneburg, Germany, 26 October 2011 – The 13th international PAS-X User Group Meeting took place from 13 to 14 October 2011 in Lueneburg, Germany, with a record attendance. On the invitation of Werum Software & Systems AG, almost 200 pharmaceuticals experts from approximately 20 countries exchanged their thoughts and ideas on the use of the PAS-X production management
Indian pharmaceutical major Dr. Reddy's chooses to implement Werum's MES
Indian pharmaceutical major Dr. Reddy's chooses to implement Werum's MES
Dr. Reddy's Laboratories Ltd. deploys PAS-X at Hyderabad site Lueneburg, Germany, August 20, 2010 – Dr. Reddy's Laboratories Ltd. has decided to introduce PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, at its site in Bachupally, Hyderabad. Dr. Reddy's plans to optimize the efficiency, quality, compliance and performance of its production processes with PAS-X. Werum is the leading supplier of MES systems for the pharmaceutical and biopharmaceutical industries
MSD Packaging Lines run with PAS-X
MSD Packaging Lines run with PAS-X
Lueneburg, Germany, August 17, 2010 - MSD deployed PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, to run its packaging line operations in Heist-op-den-Berg, Belgium in order to increase the compliance level during packaging operations and subsequently shorten lead times to improve delivery performance. Operations include fully automated blister lines and filling lines, semi-automated packaging lines and manual packaging processes. The project for introducing PAS-X was completed
Successful rollout of PAS-X MES Weighing & Dispensing at AstraZeneca in India and China
Successful rollout of PAS-X MES Weighing & Dispensing at AstraZeneca in India an …
Manufacturing Execution System projects completed successfully Lueneburg, Germany, March 25, 2010 - Manufacturing Execution System (MES) software provider Werum Software & Systems has successfully finalized the installation of PAS-X MES in AstraZeneca's Wuxi site in the Jiangsu Province, China. This first-time MES project in the Chinese pharmaceutical industry follows an employment of Werum's PAS-X MES software in AstraZeneca's Indian production site in Bengaluru (formerly Bangalore) in 2009. Both MES projects are part

All 5 Releases


More Releases for Rottapharm

Cholecystokinin Receptor (CCK) Antagonist Market 2020 New Innovations in Medical …
Cholecystokinin Receptor (CCK) Antagonist -Pipeline Insight, 2020 The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Cholecystokinin Receptor (CCK) Antagonist Market on the basis of stating current situation of the industry in 2020. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of
Diacerein Market potential growth, share, demand and analysis of key players - r …
This detailed market study covers diacerein market growth potentials which can assist the stake holders to understand key trends and prospects in diacerein market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The analysis also
Gastroesophageal Reflux Disease (GERD) Drugs and Devices Market Growth, Challeng …
"The new report has been added by qyresearch.com to provide detailed insight into the global Gastroesophageal Reflux Disease (GERD) Drugs and Devices market. The study will help to get a better understanding about the Gastroesophageal Reflux Disease (GERD) Drugs and Devices industry competitors, a channel for the distribution, Gastroesophageal Reflux Disease (GERD) Drugs and Devices growth potential, potentially disruptive trends, Gastroesophageal Reflux Disease (GERD) Drugs and Devices industry product innovations,
Diacerein Market Research and Projections for 2020-2026| TRB Pharma, Novartis, T …
Complete study of the global Diacerein market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Diacerein industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate
Best Statistical Report of Human Papillomavirus Protein E6 Market Trend Expected …
Up Market Research offers a latest published report on “Global Human Papillomavirus Protein E6 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 104 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Request Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/63749 Human Papillomavirus Protein E6 Market research report
Obsessive-Compulsive Disorder Treatment Global Outlook 2018: Novartis AG, Omeros …
Qyresearchreports include new market research report “2018-2025 Obsessive-Compulsive Disorder Treatment Report on Global and United States Market, Status and Forecast, by Players, Types and Applications” to its huge collection of research reports. The global market for Obsessive-Compulsive Disorder Treatment has been witnessing a continued alteration in the pattern of the demand for Obsessive-Compulsive Disorder Treatment. This research report attempts to understand the frequent changes in the consumer behavior and their impact